SCHEMBL2227348

SCHEMBL2227348

NS(=O)(=O)c1ccc(N2CCOCC2)c(CNc2cc(Nc3cccc(F)c3)ncn2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 7/20 0.45
JAK3 P52333 6/20 0.45
KDM4E B2RXH2 1/20 0.44
JAK1 P23458 5/20 0.43
EGFR P00533 2/20 0.43
TYK2 P29597 2/20 0.43
CSF1R P07333 1/20 0.43
ULK2 Q8IYT8 1/20 0.43
TBK1 Q9UHD2 1/20 0.43
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
SRC P12931 1/20 0.42
ERBB3 P21860 1/20 0.41
CDK2 P24941 2/20 0.40
CDK1 P06493 1/20 0.40
MTOR P42345 1/20 0.40
SMG1 Q96Q15 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2225236 0.85 TNNI3K (0.51) JAK2JAK3JAK1EGFRTYK2
SCHEMBL2225585 0.79 EGFR (0.54) KDM4EEGFRERBB3CDK2CDK1
SCHEMBL2225416 0.77 NTRK1 (0.56) JAK3EGFRERBB3CDK2
SCHEMBL12517447 0.77 TNNI3K (0.61) EGFR
Trifluoroacetic Acid SCHEMBL14323081 0.72 TNNI3K (0.54) KDM4EEGFR
SCHEMBL9980448 0.68 LRRK2 (0.42) EGFRCA12CA1CA2CA9
SCHEMBL2225414 0.68 CDK1 (0.46) EGFRCA2ERBB3CDK2CDK1
SCHEMBL9980404 0.67 STK4 (0.39) KDM4EEGFRTYK2CSF1RTBK1
SCHEMBL2226690 0.67 TNNI3K (0.64) CDK2CDK1
SCHEMBL2227241 0.67 CDK1 (0.46) EGFRCA2ERBB3CDK2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2523559-A1 COMPOUNDS AND METHODS GlaxoSmithKline LLC (US) 2012-11-21 EP claimed
WO-2011088027-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC (US) 2011-07-21 WO claimed
EP-2523559-A1 COMPOUNDS AND METHODS GlaxoSmithKline LLC (US) 2012-11-21 EP disclosed
WO-2011088027-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC (US) 2011-07-21 WO disclosed